Rankings
▼
Calendar
IMUX FY 2018 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena
IMUX
Immunic, Inc.
$138M
FY 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$15,000
Operating Income
-$42M
Net Income
-$41M
EPS (Diluted)
$-39.16
Cash Flow
Operating Cash Flow
-$43M
Free Cash Flow
-$44M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$15M
Total Liabilities
$3M
Stockholders' Equity
$12M
Cash & Equivalents
$13M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$15,000
-$998,000
+98.5%
Operating Income
-$42M
-$53M
+20.2%
Net Income
-$41M
-$52M
+20.4%
← Q4 2017
All Quarters
Q1 2018 →